Adherence and completion to multidose vaccine schedules for hepatitis A, B, and A-B are low, thereby rendering vaccination ineffective.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
Patients with chronic hepatitis B have a lower risk of hepatic events if they achieve normal on-treatment ALT in the first 12 months of NA treatment.
Of the 2500 cases of hepatitis A infection reported between January 2017 and April 2018, 68% were among persons who reported drug use (injection and non-injection), homelessness, or both.
Successful DAA therapy may lead to cognitive improvement in several domains in HCV-infected patients.
Costs were significantly higher than total annual costs per matched control with similar comorbidities.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year
A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
Future studies might focus on the use of electronic medical record warning systems or other prompts to improve diagnostic test use in at-risk individuals.
Metabolic syndrome also associated with higher alanine aminotransferase levels longitudinally
Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985
In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.
End-of-treatment HBsAg levels may be a clinically useful biomarker to predict HBV relapse in patients with chronic hepatitis B regardless of HBeAg status.
Increased adiposity in childhood may negatively impact liver function in children as young as 8 years old.
Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.
BMI is positively correlated with increased hepatocellular carcinoma in patients with chronic HBV, though the risk is greater in women.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.
TDF did not reduce mother-to-child HBV transmission in mothers taking hepatitis B Ig and HBV vaccine.
Elbasvir and grazoprevir, taken in combination for 12 weeks, successfully treated virologic response in patient with hepatitis C genotype 1b.
Technical variant grafts may be better than whole grafts for living donor liver transplants in children.
The Work Group who authored the new recommendations was made up of professionals from academic medicine, federal and state public health agencies, and medical societies.
Once daily glecaprevir-pibrentasvir for 8 or 12 weeks successfully treated HCV genotype 1 and 3.
Primary gastrinomas of the hepatobiliary tract may occur in patients with Zollinger-Ellison syndromeFebruary 15, 2018
Lymph nodes proximal to hepatic or biliary gastrinomas will likely require extraction as many in the surround region will have metastasized.
Patients with chronic HCV with a sustained virologic response were more likely to have a reduced progression of liver fibrosis.
The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.
Hepatitis B and hepatitis C may increase mortality risks in HIV patients.